Nearly 83 Percent of Early-Stage Alzheimer’s Patients Stabilize or Improve on Lecanemab
Data from the LEADER study reveal that nearly 83 percent of early-stage Alzheimer’s patients achieved disease stabilization or improvement after an average of 17 months of lecanemab treatment in clinical practice. LEADER Study Findings Blisko 83 proc. pacjentów z chorobą Alzheimera na...


